Maintenance therapy with monoclonal antibodies in metastatic HER2-positive breast cancer: A review of studies

Authors

  • Elena Chistyakova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation
  • Rashida Orlova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2023.105

Abstract

Maintenance therapy is a medical treatment after achieving stabilization, partial or complete response by the first line therapy of a metastatic malignant tumor. The goals of such treatment are to maintain the effect of the first line therapy, to increase progression-free survival, and, in some cases, overall survival. Targeted monoclonal antibody therapy is a maintenance treatment option widely used in clinical practice for metastatic HER2-positive breast cancer, but it remains one of the least studied. This analysis of available world studies was carried out in order to form an idea about the possibilities of maintenance therapy and promising areas for studying this topic. The article presents an up-to-date and complete review of data
on metastatic HER2-positive breast cancer maintenance therapy with various drugs from the monoclonal antibody group, as well as cases of discontinuation of maintenance therapy due to high toxicity or at the request of the patient. Besides, authors analyzed the treatment options of maintenance therapy in patients with luminal HER2-positive breast cancer and the possibilities of intensifying monoclonal antibody maintenance therapy by antihormonal drugs for this group of patients.

Keywords:

maintenance therapy, metastatic breast cancer, trastuzumab, pertuzumab

Downloads

Plum Print visual indicator of research metrics
No metrics available.
-
see details
 

References


References

Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. The Oncologist, 2008, vol. 13, pp. 515–25.

Gullo G., Zuradelli M., Sclafani F., Santoro A., Crown J. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Annals of Oncology, 2012,vol. 23, pp. 2204–2208.

Swain S. M., Miles D., Kim S. B., Im Y. H., Im S. A., Semiglazov V., Ciruelos E., Schneeweiss A., Loi S., Monturus E., Clark E., Knott A., Restuccia E., Benyunes M. C., Cortés J. CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA):end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncology,2020, vol. 21, no. 4, pp. 519–530. https://doi.org/10.1016/S1470-2045(19)30863-0

Helwick C. Expert Point of View: John T. Cole, MD, and Carlos H. Barrios, MD. The ASCO Post.Available at: https://ascopost.com/issues/july-10-2019/epov-john-cole-and-carlos-barrios/ (accessed:20.01.2023).

Hsieh A., Pittman K., Patterson W. K., Townsend A. Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer? BMJ Case Rep., 2015: bcr2014207750. https://doi. org/10.1136/bcr-2014-207750

Niikura N., Shimomura A., Fukatsu Y., Sawaki M., Ogiya R., Yasojima H., Iwata H. Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. Breast Cancer Research and Treatment, 2017, vol. 167, no. 1, pp. 81–87. https://doi.org/10.1007/s10549-017-4489-9

Yardely D. A., Tripathy D., Brusfsky A. M., Rugo H. S., Kaufman P. A., Mayer M., Magidson J., Yoo B.,Quah C., Yood M. U. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. British Journal of Cancer, 2014, vol. 110, pp. 2756–2764.

Gullo G., Zuradelli M., Kelleher F., Sclafani F. 5000 ORAL Long-term outcome of HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) achieving durable complete remission (DCR) after trastuzumab (T)-containing chemotherapy (CT). The European Journal of Cancer, Abstract Book,European Multidisciplinary Cancer Congress, 2011, vol. 47 (Suppl), pp. 329–330.

Rossi S., Basso M., Strippoli A., Dadduzio V. Cerchiaro Е. Barile R. D’Argento E. Cassano А., Schinzari G. Barone С. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clinical Breast Cancer, 2015,vol. 15, pp. 307–312. https://doi.org/.org/10.1016/j.clbc.2015.03.010

Rivenbark A. G., O’Connor S. M., Coleman W. B. Molecular and cellular heterogeneity in breast cancer:challenges for personalized medicine. The American Journal of Pathology, 2013, vol. 183, no. 4,pp. 1113–1124. https://doi.org/10.1016/j.ajpath.2013.08.002

Rimawi M., Ferrero J. M., de la Haba-Rodriguez J., Poole C., De Placido S., Osborne C. K., Hegg R.,Easton V., Wohlfarth C., Arpino G. PERTAIN Study Group. First-Line Trastuzumab Plus an Aromatase Inhibitor, with or without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 2018, vol. 36, no. 28, pp. 2826–2835. https://doi.org/10.1200/JCO. 2017.76.7863

Downloads

Published

2023-06-18

How to Cite

Chistyakova, E. ., & Orlova, R. . (2023). Maintenance therapy with monoclonal antibodies in metastatic HER2-positive breast cancer: A review of studies. Vestnik of Saint Petersburg University. Medicine, 18(1), 63–69. https://doi.org/10.21638/spbu11.2023.105

Issue

Vol. 18 No. 1 (2023)

Section

Oncology

License

Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.